Healthcare IT
MMIT helps pharma companies harness the power of real world data to better understand the patient journey.
Twelve specialty pharmacies recognized for their dedication to top-quality customer services.
One of the first steps in your therapy’s commercialization journey should be to identify high-value HCPs who can help guide valuation, messaging and more.
Our Zitter Insights Panel uses research to illuminate the complexities of market access.
Industry Leading Insights
MMIT offers a range of publications for pharma, payers and providers covering news, strategy and insights across the spectrum. Our in-house journalism division AIS Health provides objective news and analysis of industry trends while RJ Health provides a comprehensive look at industry updates as they apply to medically covered drug reimbursement processes.
When it comes to the degree of payer management within a therapeutic area, pharma companies are becoming the victim of their own successes.
It has now been over a year since the first Humira biosimilar, Amgen’s Amjevita, entered the U.S. market. Eight additional adalimumab biosimilars followed suit, offering lower-cost alternatives to AbbVie’s blockbuster drug via a variety of dual-pricing and discounting strategies.
In our collective experience working with dozens of clients, we’ve found that smaller pharma companies and biotechs wrestle with many common challenges, regardless of their therapeutic area.
Manufacturers are continuing to wrestle with the effects of the Inflation Reduction Act (IRA) on their business plans and revenue streams.
The category of treatments known as ‘digital therapeutics’ is widely misunderstood. Though the term is often conflated with ‘digital health’ tools, such as fitness trackers or meditation apps, digital therapeutics (DTx) are distinguished by their reliance on clinical evidence.
Many years ago, I became one of the first people to be diagnosed with an ultra-rare vasculitis syndrome, a dangerous inflammation of the small blood vessels. My disease is so rare that I had a much better chance of winning the lottery, but instead, I ended up sick.
Get the latest from MMIT’s leading subject matter experts, receiving the latest posts right to your inbox. Top-quality thought leadership 100% free.
March 20, 2024
Managed Markets Insight & Technology (MMIT), the trusted go-to-market partner for overcoming barriers to patient access, has announced the finalists of its ninth Specialty Pharmacy Patient Choice Awards.
February 14, 2024
This review of current benefit designs uses MMIT’s data on commercial plans’ use of copay accumulators and maximizers.
January 18, 2024
The increased popularity of anti-obesity medications is raising questions about inequities in patient access, due to both shortages and limited payer coverage policies.
January 17, 2024
The application of AI will expand into managed care organizations in the near future. For payers and PBMs, AI tools can be useful for tasks including claims processing, prior authorization review, and data retrieval.
January 14, 2024
Biosimilars offer substantial promise for a new era of accessibility and affordability for patients, but better understanding of these products from payers and providers is necessary for biosimilars to reach their full potential.
January 2, 2024
By blending claims, lab, and EHR data with payer coverage and clinical pathway data, pharma companies can gain full visibility into what’s happening in the market before they launch.
December 4, 2023
Patient Access Analytics received the Gold Award for Technology Solutions in Healthcare.
November 29, 2023
Life sciences companies will face several challenges in the new year, from more pressure on pipelines to the ongoing consequences of regulatory changes. Norstella experts share their predictions.
October 9, 2023
Many oncology manufacturers assume that a therapy’s inclusion on clinical pathways is more important than its coverage profile, but this isn’t always true.
September 15, 2023
Insulin price caps and list price reductions are a huge step forward for patient access. But what will these changes mean for health plans?
September 13, 2023
Rebate leakage drains millions in revenue from pharma companies every year. To ensure contract compliance, manufacturers can implement these five steps.
September 13, 2023
Buy-and-bill remains the most common distribution channel for provider-administered oncology drugs, but pharmacy channels are still significant, especially for hospital outpatient departments.
September 12, 2023
Infusing a commercialization strategy with real-world data provides a more holistic view of the patient journey.
July 1, 2023
Preliminary data indicate that 2023 may prove to be the most volatile year for health plan enrollment in a decade.
May 31, 2023
The shot’s clearance comes several weeks after the regulator made GSK’s Arexvy the first vaccine for RSV in the U.S.
May 15, 2023
Over the past few decades, pharma companies have perfected the art of using market access data to support product launches, negotiate payer discounts, and secure preferred status and positioning.
May 5, 2023
The Senate Health, Education, Labor and Pensions (HELP) Committee went to work this week to find a bipartisan consensus on measures to reduce prescription drug costs.